Journal of Blood Medicine
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia
(5332) Total Article Views
Authors: Lisa M Lima, Martha Arellano, Stacie Holloway, et al
Published Date September 2010
Volume 2010:1 Pages 221 - 225
Lisa M Lima, Martha Arellano, Stacie Holloway, Marian Shepard, Stephanie McMillan, Hanna Jean Khoury
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
Abstract: Dasatinib (DAS) is a well tolerated oral dual SRC inhibitor with remarkable activity against all phases of imatinib-resistant chronic myeloid leukemia (CML). This paper focuses on the activity of DAS in intractable CML, and reviews outcomes of patients enrolled on DAS clinical trials. Safety and tolerability as well as practical tips for management of side-effects, and drug interactions are included.
Keywords: dasatinib, resistant CML, outcomes
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Other articles by Dr Jean Khoury
Readers of this article also read:
Call For Submissions
Submit Original Research Article, Review, Case Report, or Rapid Communication in Journal of Blood Medicine
- Treatment of anemia in chronic kidney disease: known, unknown, and both
- Treatment of hemophilia: a review of current advances and ongoing issues
- Use of sulodexide in patients with peripheral vascular disease
- Deep vein thrombosis: a clinical review